Evidence map›Paper›PMID 40699238›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Molecular regulation by ubiquitin-specific proteases (USPs) in HCC: cell cycle, oncogenic signaling, and beyond.

Furqan N Al-Khateeb, Asraa Yacoob Yousif, Sarmad Ghazi Al-Shawi, Ali G Alkhathami, Roopashree R, Aditya Kashyap, Deepak Nathiya, Subhashree Ray, Mohammed Jawad Alnajar, Muthana Kareem

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Furqan N Al-KhateebCollege of Pharmacy, University of Al Maarif, Al Anbar, 31001, Iraq. furqan.nsaif@uoa.edu.iq.
Asraa Yacoob YousifAnimal Production Department, College of Agriculture, University of Basrah, Basrah, Iraq.
Sarmad Ghazi Al-ShawiFood Science Department, College of Agriculture, University of Basrah, Basrah, Iraq. sarmad.mohammed@uobasrah.edu.iq.
Ali G AlkhathamiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Roopashree RDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Aditya KashyapCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Deepak NathiyaDepartment of Pharmacy Practice, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India.
Subhashree RayDepartment of Biochemistry, IMS and SUM Hospital, Siksha O Anusandhan (Deemed to Be University), Bhubaneswar, Odisha-751003, India.
Mohammed Jawad AlnajarDepartment of Pharmacy, Al-Nisour University College, Nisour Seq. Karkh, Baghdad, Iraq.
Muthana KareemDepartment of Medical Analysis, Medical Laboratory Technique College, The Islamic University, Najaf, Iraq.

Funding

King Khalid University RGP.02/534/44
6 · The paper itself

Abstract

Ubiquitin-specific proteases (USPs) are a large family of deubiquitinating enzymes that all serve the important function of removing ubiquitin moieties from target proteins, thereby maintaining cellular homeostasis. Post-translational modifications, including ubiquitin modifications, play a crucial role in regulating protein stability, localization, and function, thereby profoundly influencing cellular processes such as cell cycle progression, signal transduction, and the response to DNA damage. Increasingly extensive evidence indicates that altered USP activity creates dysfunction of these fundamental cellular pathways and initiates and promotes multiple cancers, including hepatocellular carcinoma (HCC). In HCC, aberrant USP activity directly alters tumor cell proliferation and survival pathways, as well as metastasis, by manipulating oncogenic signaling networks and cellular stress responses. The altered expression or function of multiple USPs has been associated with aggressiveness and poor clinical outcomes, suggesting that USPs may have potential as prognostic biomarkers. Additionally, USPs are ideal therapeutic targets because their enzymatic activity can be selectively inhibited, thereby restoring normal ubiquitination-dependent signaling pathways that are frequently hijacked in cancer. The goal of this review is to provide an overview of current knowledge on the roles of USPs in HCC pathogenesis, with an emphasis on our understanding of their combined effect on major biological processes that underpin or augment tumor development. We highlight our understanding of how USPs regulate oncogenic pathways and cellular behavior in HCC, which forms the basis for this important area of future research aimed at developing novel USP-based therapies. Understanding USP biology in HCC represents a significant opportunity to inform the development of new cancer therapies.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsUbiquitin-Specific ProteasesAnimalsCell CycleHumansSignal TransductionUbiquitin-Specific ProteasesHepatocellular carcinomaPrognosisSignaling pathwayTherapeuticUbiquitin-specific proteases

Identifiers

PMID40699238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.